» Authors » Mosunmoluwa Oyenuga

Mosunmoluwa Oyenuga

Explore the profile of Mosunmoluwa Oyenuga including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 46
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Onyeaghala G, Sharma S, Oyenuga M, Staley C, Milne G, Demmer R, et al.
Microorganisms . 2024 Aug; 12(8). PMID: 39203451
Several bacterial taxa enriched in inflammatory bowel diseases and colorectal cancer (CRC) are found in the oral cavity. We conducted a pilot study nested within a six-week aspirin intervention in...
2.
Vivek S, Shen Y, Guan W, Onyeaghala G, Oyenuga M, Staley C, et al.
Int J Mol Sci . 2024 Jul; 25(13). PMID: 38999941
Though the microbiome's impact on immune system homeostasis is well documented, the effect of circulating T cells on the gut microbiome remains unexamined. We analyzed data from 50 healthy volunteers...
3.
Onyechi A, Ohemeng-Dapaah J, Patel R, Onyechi E, Oyenuga M, Sartaj S, et al.
J Community Hosp Intern Med Perspect . 2023 Oct; 13(5):86-89. PMID: 37868679
Drug-induced immune hemolytic anemia (DIIHA) is a relatively uncommon cause of anemia, and its diagnosis can be challenging. Although beta-lactam antimicrobial agents are often associated with DIIHA, any medication can...
4.
Onyechi A, Ohemeng-Dapaah J, Shaba W, Oyenuga M, Lacasse A, Sandeep S, et al.
J Community Hosp Intern Med Perspect . 2023 Oct; 13(5):82-85. PMID: 37868674
Acute intermittent porphyria (AIP) is a rare disease that arises due to deficiency of the biosynthetic enzyme porphobilinogen deaminase (PBGD) involved in heme synthesis. Acute attacks can present with abdominal...
5.
Patel R, Onyechi A, Mohamed M, Oyenuga M, Sartaj S
Cureus . 2023 Jun; 15(5):e38838. PMID: 37303368
In advanced renal cell carcinoma, few randomized controlled trials involving immunotherapy plus antiangiogenic therapy have shown survival benefits relative to Sunitinib. Our meta-analysis aimed to evaluate the efficacy and safety...
6.
Oyenuga M, Halabi S, Oyenuga A, McSweeney S, Morgans A, Ryan C, et al.
Prostate . 2023 Feb; 83(7):688-694. PMID: 36842158
Background: A prognostic risk score (Halabi score) in metastatic castration-resistant prostate cancer (mCRPC) accurately predicts overall survival, but its association with quality of life (QOL) has not been defined. We...
7.
Oyenuga M, Mohamed M, Patel R, Sartaj S, Sen S, Lacasse A, et al.
J Community Hosp Intern Med Perspect . 2023 Feb; 12(6):69-72. PMID: 36816171
Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, Skin changes (POEMS) syndrome is a rare disorder with multiple presentations and a constellation of symptoms. We present a 62 year-old female who presented to the...
8.
Oyenuga M, Sen S, Patel R, Ali S, Sartaj S, Lacasse A
J Community Hosp Intern Med Perspect . 2022 Oct; 12(5):106-109. PMID: 36262488
Sarcomas are a broad group of neoplasm that originate from the mesenchymal layer and represent about 1% of malignancy in the adult population. We describe a 46-year-old woman with no...
9.
Oyenuga M, Mohamed M, Sartaj S, Patel R, Oyenuga A, Sen S
Immunopharmacol Immunotoxicol . 2022 Aug; 45(1):10-15. PMID: 36017642
Background: Immune checkpoint inhibitors (ICI) have revolutionized care in oncology with improved overall survival in several cancer populations. Nivolumab has recently been approved for use in patients with upper gastrointestinal...
10.
Barclay E, Ojo I, Hake A, Oyenuga A, Satrom K, Lund T, et al.
Am J Trop Med Hyg . 2022 Jul; 107(2):328-335. PMID: 35895425
Severe neonatal jaundice (SNNJ) is a leading cause of neonatal morbidity and mortality in low- and middle-income countries (LMICs). Risk mitigation and management modalities for SNNJ have led to marked...